Vancouver, British Columbia - BioMark Diagnostics Inc. (BUX:CNX) (FSE: 20B) (BMKDF) is pleased to announce that BioMark has been selected to present at 11th Annual Conference of the Metabolomics Society.
“BioMark has been accepted to be a presenter at the 11th annual conference of the Metabolomics Society, to be held in San Francisco/Burlingame between June 29 and July 02, 2015. Over 700 abstract submissions have been received. All abstracts were scored by the International Organizing Committee by around six reviewers per abstract to yield a fair score. BioMark has been selected to present a 90 minute long poster presentation in the session provisionally titled "poster session 1-3". We very much look forward to an exciting meeting,” says Oliver Fiehn, PhD Chairman For Organizing Committee, Metabolomics Society
President and CEO, Rashid Ahmed is delighted to have this opportunity to present BioMark’s technology in the rapidly expanding field of metabolomics with partners from TMIC, a Genome Canada-funded Science and Technology Innovation Centre located at the University of Alberta and University of Victoria.
President and CEO of BioMark, Rashid Ahmed says: “Metabolomics for diagnostic application is a crucial component of BioMark’s cancer detection and monitoring platform.”
About BioMark Diagnostics Inc.
BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer, early and cost effectively. BioMark is currently conducting Phase 3 multi site clinical trial for lung, breast, gastro intestinal and prostate cancers. Additionally trials related to assess response to lung cancer treatment and surgical interventions are being established.
For further information on BioMark, please Contact:
Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Biomark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The CSE has not reviewed, approved or disapproved the content of this press release.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer